ParkinsonCanadaV1, Main, Exploration, bibRecord, 000D01

Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease

Identifieur interne : 000D01 ( Main/Exploration ); précédent : 000D00; suivant : 000D02

Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease

Auteurs : Amaal Aldakheel ; Lorraine V. Kalia ; Anthony E. Lang

Source :

Neurotherapeutics [ 1933-7213 ] ; 2013.

RBID : PMC:3899477

English descriptors

KwdEn :
- Animals, Antioxidants (therapeutic use), Disease Models, Animal, Dopamine Agents (therapeutic use), Humans, Neuroprotective Agents (therapeutic use), Parkinson Disease (drug therapy), Reactive Oxygen Species (metabolism).
MESH :
- chemical , metabolism : Reactive Oxygen Species.
- chemical , therapeutic use : Antioxidants, Dopamine Agents, Neuroprotective Agents.
- drug therapy : Parkinson Disease.
- Animals, Disease Models, Animal, Humans.

Abstract

Parkinson disease is an inexorably progressive neurodegenerative disorder. Multiple attempts have been made to establish therapies for Parkinson disease which provide neuroprotection or disease modification—two related, but not identical, concepts. However, to date, none of these attempts have succeeded. Many challenges exist in this field of research, including a complex multisystem disorder that includes dopaminergic and non-dopaminergic features; poorly understood and clearly multifaceted disease pathogenic mechanisms; a lack of reliable animal models; an absence of effective biomarkers of disease state, progression, and target engagement; and the confounding effects of potent symptomatic therapy. In this article, we will review previous, ongoing, and potential future trials designed to alter the progressive course of the disease from the perspective of the targeted underlying pathogenic mechanisms.

Electronic supplementary material

The online version of this article (doi:10.1007/s13311-013-0218-1) contains supplementary material, which is available to authorized users.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899477

DOI: 10.1007/s13311-013-0218-1
PubMed: 24085420
PubMed Central: 3899477

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease</title>
<author><name sortKey="Aldakheel, Amaal" sort="Aldakheel, Amaal" uniqKey="Aldakheel A" first="Amaal" last="Aldakheel">Amaal Aldakheel</name>
<affiliation><nlm:aff id="Aff1">Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson’s Disease, Toronto Western Hospital, University Health Network, Toronto, ON Canada</nlm:aff>
<wicri:noCountry code="subfield">ON Canada</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kalia, Lorraine V" sort="Kalia, Lorraine V" uniqKey="Kalia L" first="Lorraine V." last="Kalia">Lorraine V. Kalia</name>
<affiliation><nlm:aff id="Aff1">Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson’s Disease, Toronto Western Hospital, University Health Network, Toronto, ON Canada</nlm:aff>
<wicri:noCountry code="subfield">ON Canada</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><nlm:aff id="Aff2">Movement Disorders Unit, Toronto Western Hospital, 399 Bathurst Street, 7 McLaughlin Wing, Toronto, M5T 2S8 ON Canada</nlm:aff>
<wicri:noCountry code="subfield">M5T 2S8 ON Canada</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24085420</idno>
<idno type="pmc">3899477</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899477</idno>
<idno type="RBID">PMC:3899477</idno>
<idno type="doi">10.1007/s13311-013-0218-1</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">000271</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000271</idno>
<idno type="wicri:Area/Pmc/Curation">000271</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000271</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000605</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000605</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000820</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000820</idno>
<idno type="wicri:Area/PubMed/Curation">000820</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000820</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000820</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000820</idno>
<idno type="wicri:Area/Ncbi/Merge">001577</idno>
<idno type="wicri:Area/Ncbi/Curation">001577</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001577</idno>
<idno type="wicri:doubleKey">1933-7213:2013:Aldakheel A:pathogenesis:targeted:disease</idno>
<idno type="wicri:Area/Main/Merge">000D10</idno>
<idno type="wicri:Area/Main/Curation">000D01</idno>
<idno type="wicri:Area/Main/Exploration">000D01</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease</title>
<author><name sortKey="Aldakheel, Amaal" sort="Aldakheel, Amaal" uniqKey="Aldakheel A" first="Amaal" last="Aldakheel">Amaal Aldakheel</name>
<affiliation><nlm:aff id="Aff1">Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson’s Disease, Toronto Western Hospital, University Health Network, Toronto, ON Canada</nlm:aff>
<wicri:noCountry code="subfield">ON Canada</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kalia, Lorraine V" sort="Kalia, Lorraine V" uniqKey="Kalia L" first="Lorraine V." last="Kalia">Lorraine V. Kalia</name>
<affiliation><nlm:aff id="Aff1">Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson’s Disease, Toronto Western Hospital, University Health Network, Toronto, ON Canada</nlm:aff>
<wicri:noCountry code="subfield">ON Canada</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><nlm:aff id="Aff2">Movement Disorders Unit, Toronto Western Hospital, 399 Bathurst Street, 7 McLaughlin Wing, Toronto, M5T 2S8 ON Canada</nlm:aff>
<wicri:noCountry code="subfield">M5T 2S8 ON Canada</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">Neurotherapeutics</title>
<idno type="ISSN">1933-7213</idno>
<idno type="eISSN">1878-7479</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antioxidants (therapeutic use)</term>
<term>Disease Models, Animal</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Humans</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Reactive Oxygen Species (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Reactive Oxygen Species</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antioxidants</term>
<term>Dopamine Agents</term>
<term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Parkinson disease is an inexorably progressive neurodegenerative disorder. Multiple attempts have been made to establish therapies for Parkinson disease which provide neuroprotection or disease modification—two related, but not identical, concepts. However, to date, none of these attempts have succeeded. Many challenges exist in this field of research, including a complex multisystem disorder that includes dopaminergic and non-dopaminergic features; poorly understood and clearly multifaceted disease pathogenic mechanisms; a lack of reliable animal models; an absence of effective biomarkers of disease state, progression, and target engagement; and the confounding effects of potent symptomatic therapy. In this article, we will review previous, ongoing, and potential future trials designed to alter the progressive course of the disease from the perspective of the targeted underlying pathogenic mechanisms.</p>
<sec><title>Electronic supplementary material</title>
<p>The online version of this article (doi:10.1007/s13311-013-0218-1) contains supplementary material, which is available to authorized users.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Aldakheel, Amaal" sort="Aldakheel, Amaal" uniqKey="Aldakheel A" first="Amaal" last="Aldakheel">Amaal Aldakheel</name>
<name sortKey="Kalia, Lorraine V" sort="Kalia, Lorraine V" uniqKey="Kalia L" first="Lorraine V." last="Kalia">Lorraine V. Kalia</name>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D01 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D01 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3899477
   |texte=   Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:24085420" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease

Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.